Cognito, Ochsner Launch Brain Health Collaboratory Initiative

Cognito Therapeutics has partnered with Ochsner Health to establish a new Brain Health Collaboratory aimed at advancing innovative approaches to treating cognitive decline and Alzheimer’s disease. The initiative marks a significant step toward integrating emerging neurotechnology into real-world clinical care across the Gulf South region.

The collaboration creates the first statewide platform in the region focused on non-invasive brain health innovation. By combining Cognito’s investigational Spectris™ technology with Ochsner’s extensive clinical network, the program seeks to develop new care delivery models for patients in both urban and rural communities across Louisiana, Mississippi, and surrounding areas.

At the heart of the initiative is Cognito’s Spectris platform, a non-invasive neurotechnology designed for at-home use. The device delivers synchronized light and sound stimulation through the brain’s sensory pathways to promote healthy neural activity. Early research suggests it may help preserve brain structure and function in patients with Alzheimer’s disease and potentially other neurological conditions. The therapy has already received Breakthrough Device Designation from the U.S. Food and Drug Administration and is currently being evaluated in clinical trials.

The Brain Health Collaboratory will also focus on developing a “Brain Health Index,” a framework intended to track cognitive performance, disease progression, and treatment response in real-world settings. By standardizing how brain health is measured, the partners aim to improve clinical decision-making and accelerate the adoption of new therapies.

According to David Houghton, the collaboration offers an opportunity to bridge cutting-edge neurotechnology with everyday patient care. He emphasized that understanding how to slow cognitive decline and improve quality of life could open new therapeutic pathways not only for Alzheimer’s disease but also for other neurological disorders.

Ochsner’s expanding neuroscience infrastructure will play a key role in the initiative. The health system is set to open the Debra H. and Robert J. Patrick Neuroscience Institute in New Orleans in late 2026, a 132,000 square-foot facility that will centralize its neuroscience programs and enhance patient access to advanced care.

Christian Howell highlighted the importance of reaching a broad patient population, noting that partnerships with large health systems enable innovative therapies to move beyond academic centers and into everyday clinical practice. Expanding access, he said, is essential for generating real-world evidence and improving outcomes for patients living with neurodegenerative diseases.

The collaboratory will also explore integration of Spectris into value-based care models, including programs for Medicare and Medicaid populations, where Alzheimer’s disease presents significant clinical and economic challenges. By evaluating cost-effectiveness and care coordination, the initiative aims to demonstrate how non-invasive therapies can fit into broader healthcare systems.

This partnership builds on Cognito’s earlier Brain Health Collaboratory launched in 2025 and reflects its broader strategy to create a network of innovation hubs. Together, Cognito and Ochsner aim to accelerate the transition of breakthrough neurotechnologies from research into routine clinical use, ultimately transforming the future of brain health care.